PO-1378 Isotoxic high-dose SBRT versus CRT for localized pancreatic cancer : a single center evaluation
Martin Manderlier(Université Libre de Bruxelles), Christelle Bouchart(Université Libre de Bruxelles), Jean Closset(Erasmus Hospital), Jean-Luc Engelholm(Université Libre de Bruxelles), Matthieu Hein(Université Libre de Bruxelles), Julie Navez(Université Libre de Bruxelles), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Dirk Van Gestel(Université Libre de Bruxelles), L. Moretti(Université Libre de Bruxelles), Jean–Luc Van Laethem
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
Pancreatic-fluid collections: a randomized controlled trial regarding stent removal after endoscopic transmural drainage
|Gastrointestinal Endoscopy|2007|286